复方甘草酸苷片联合左西替利嗪对慢性荨麻疹患者血清学指标及免疫功能的影响  

The Influence of Compound Glycyrrhizin Tablets Combined with Levocetirizine on Serological Indicators and Immune Function in Patients with Chronic Urticaria

作　　者：张涛[1] 余瑶[2] ZHANG Tao;YU Yao(Department of Dermatology, Dechang People＇s Hospital, Dechang 615500, China;Department of Dermatology, West China Hospital of Sichuan University, Chengdu 610000, China)

机构地区：[1]德昌县人民医院皮肤科,四川德昌615500 [2]四川大学华西医院皮肤科,四川成都610000

出　　处：《标记免疫分析与临床》2018年第6期871-874,906,共5页Labeled Immunoassays and Clinical Medicine

摘　　要：目的研究复方甘草酸苷片联合左西替利嗪对慢性荨麻疹(CU)患者血清学指标及免疫功能的影响。方法将84例CU患者随机分成治疗组和对照组各42例。对照组给予左西替利嗪治疗,治疗组在对照组基础上加用复方甘草酸苷片,均持续4周。于治疗前(T1)及治疗4周后(T2)检测两组患者血清细胞因子[单核细胞趋化蛋白-1(MCP-1)、嗜酸性粒细胞趋化因子(Eotaxin)]、急性时相反应蛋白[前白蛋白(PA)、补体(C3、C4)]水平、红细胞免疫相关指标[红细胞受体花环率(RBC-C3bRR)、红细胞免疫复合物花环(RBC-ICR)]和外周血T淋巴细胞亚群(CD4^+、CD8^+)分布情况,观察两组患者CU症状和生活质量[皮肤病生活质量指数(DLQI)]改善情况,记录不良反应发生情况。结果 T1时,两组血清细胞因子、急性时相反应蛋白、红细胞免疫相关指标、外周血T细胞亚群、CU症状和生活质量检测或评估结果无明显差异(P>0.05)。T2时,两组血清细胞因子(MCP-1、Eotaxin)水平、红细胞免疫相关指标(RBC-C3bRR、RBC-ICR)、CD8^+、CU症状积分和DLQI评分均较T1时降低,且治疗组低于对照组(P<0.05);急性时相反应蛋白(PA、C3、C4)水平、CD4^+则均较T1时显著上升,且治疗组高于对照组(P<0.05)。两组不良反应率无明显差异(P>0.05)。结论复方甘草酸苷片联合左西替利嗪可调节CU患者免疫功能和防御机制、改善其疾病症状和生活质量,安全性良好,于病情转归有利。Objective To study the influence of Compound Glycyrrhizin Tablets combined with levocetirizine on serological indicators and immune function in patients with chronic urticaria. Methods 84 patients with chronic urticaria were randomly divided into the treatment group and the control group with 42 patients in each group. The two groups were treated with levocetirizine, and the treatment group was additionally treated with Compound Glycyrrhizin Tablets. The treatment in two groups lasted for 4 weeks. Levels of serum cytokines ~ monocyte chemoattractant protein - 1 （ MCP- 1 ）, eosinophil chemotactic factor （ Eotaxin ） , peripheral blood T lymphocyte subsets （CD4 ^＋ , CD8 ^＋）, red cell immune related indicators [ red blood cell - receptor rosette rate （RBC-C3bRR）, red blood cell -immune complex rosette （RBC-ICR） , and acute phase proteins E prealbumin （ PA）, complements （ C3, C4） ] in two groups were detected before treatment （ T1 ） and after 4 week treatment （T2）. The relief of chronic urticaria symptoms and improvement of quality of life [ dermatology life quality index （ DLQI ） ] in two groups were observed, and the occurrence of adverse reactions was observed. Results There was no significant difference in serum cytokines, acute phase reaction protein, red blood cell immune related indexes, peripheral blood T cell subsets, CU symptoms and quality of life between the two groups at T1 （ P 〉 0.05 ）. At T2,1evels of serum cytokines （ MCP- 1, Eotaxin）, red blood cell immune related indexes （RBC-C3bRR,RBC-ICR）, CD8^＋ , CU symptom scores and DLQI scores in the two groups were all lower than those at T1, showing the treatment group 〈 the control group （ P 〈 0.05 ）. However, levels of acute phase reactive protein （PA, C3, C4）and CD4^＋ were significantly higher than those at T1, showing the treatment group 〉 the control group （ P 〈 0.05 ）. There was no significant difference in the adverse reactions rate between the two groups （ P 〉 0.05

关 键 词：复方甘草酸苷片 左西替利嗪 慢性荨麻疹 免疫功能 防御机制 

分 类 号：R512.62[医药卫生—内科学]